Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...